Griesinger F, et al. - In this systematic review and meta-analysis, researchers assessed the relative effectiveness, safety, and health-related quality of life (HRQoL) of carboplatin- vs cisplatin-based chemotherapy in first-line non-small cell cancer. Of the 4,139 records for inclusion in the meta-analysis, 12 RCTs (2,048 patients) were identified. This updated evidence base confirms results from past meta-analyses indicating no distinction in overall survival between carboplatin- and cisplatin-based chemotherapy, despite a slight advantage for cisplatin in objective response rate. Toxicity profiles should be taken into account in the selection of treatment along with the comorbidities of patients. For thrombocytopenia, anaemia, neurotoxicity, and the risk of nausea/vomiting, differences in drug-related toxicities were noted between carboplatin- and cisplatin-based chemotherapy.